Could a daily pill help save sight in diabetic retinopathy?

NCT ID NCT04692688

Completed Disease control Sponsor: Ocuphire Pharma, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an oral medication called APX3330 in 103 adults with moderate to severe diabetic retinopathy, a leading cause of vision loss. The pill aims to reduce inflammation and low-oxygen stress in the eye. Researchers measured whether the drug could improve the severity of the disease over 24 weeks compared to a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: APX3330 (an oral tablet that targets inflammation and low-oxygen signals in the eye)
What this could lead to: If it works, this could provide a convenient pill-based option to slow or improve diabetic retinopathy, reducing the need for eye injections or laser treatment.
What could go wrong: This is a small Phase 2 trial with only 103 participants, so results may not be conclusive. The drug may not show enough benefit or could have side effects not yet seen.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

background diabetic retinopathy diabetes mellitus diabetic macular edema diabetic retinopathy proliferative diabetic retinopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC MACULAR EDEMA DIABETIC RETINOPATHY NPDR - NON PROLIFERATIVE DIABETIC RETINOPATHY PDR - PROLIFERATIVE DIABETIC RETINOPATHY

Contacts and locations

Locations

Clinical Site 1

Rapid City, South Dakota, 57701, United States
Clinical Site 10

Fort Worth, Texas, 76104, United States
Clinical Site 11

Palm Desert, California, 92260, United States
Clinical Site 12

Albuquerque, New Mexico, 87113, United States
Clinical Site 13

Southlake, Texas, 76092, United States
Clinical Site 14

Hagerstown, Maryland, 21740, United States
Clinical Site 15

Shirley, New York, 11967, United States
Clinical Site 16

Bellaire, Texas, 77030, United States
Clinical Site 17

Grand Blanc, Michigan, 48439, United States
Clinical Site 18

Austin, Texas, 78705, United States
Clinical Site 19

Miami, Florida, 33143, United States
Clinical Site 2

Sacramento, California, 95825, United States
Clinical Site 20

Charlotte, North Carolina, 28210, United States
Clinical Site 21

Ogden, Utah, 84010, United States
Clinical Site 22

Springfield, Massachusetts, 01107, United States
Clinical Site 23

San Antonio, Texas, 78624, United States
Clinical Site 24

Walnut Creek, California, 94598, United States
Clinical Site 3

San Antonio, Texas, 78240, United States
Clinical Site 4

McAllen, Texas, 78550, United States
Clinical Site 5

Beverly Hills, California, 91607, United States
Clinical Site 6

Carmel, Indiana, 46290, United States
Clinical Site 7

Winter Haven, Florida, 33880, United States
Clinical Site 8

Bakersfield, California, 93309, United States
Clinical Site 9

Phoenix, Arizona, 85014, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.